Novel nanoplatforms known as GCMNPs, composed of a core of glycyrrhetinic acid and poly(lactic‐co‐glycolic acid) wrapped in a leukocyte membrane, effectively lower GPX4 expression in AML cells. The gene discussed is GPX4; the disease is acute myeloid leukemia.